Press Releases
Keyword Search
01.04.23
OpGen Announced 1-for-20 Reverse Stock Split
12.13.22
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
11.10.22
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
10.27.22
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
10.27.22
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update
10.25.22
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
10.03.22
OpGen Announces Closing of $3.38 Million Registered Direct Offering
10.03.22
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
09.30.22
OpGen Announces $3.38 Million Registered Direct Offering
09.20.22
OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform